You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Litigation Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)


✉ Email this page to a colleague

« Back to Dashboard


United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)

Docket ⤷  Try a Trial Date Filed 2020-06-04
Court District Court, D. Delaware Date Terminated 2022-09-09
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To Jennifer L. Hall
Parties LIQUIDIA TECHNOLOGIES, INC.
Patents 10,029,011; 10,036,037; 6,458,462; 6,521,212; 6,756,033; 6,765,117; 7,417,070; 7,544,713; 7,999,007; 8,067,025; 8,114,021; 8,222,010; 8,497,393; 9,000,002; 9,108,015; 9,339,507; 9,358,240; 9,567,578; 9,593,066; 9,604,901
Attorneys Erik B. Milch
Firms DLA Piper LLP (US)
Link to Docket External link to docket
Small Molecule Drugs cited in United Therapeutics Corporation v. Liquidia Technologies, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .
Biologic Drugs cited in United Therapeutics Corporation v. Liquidia Technologies, Inc.

The biologic drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .

Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)

Date Filed Document No. Description Snippet Link To Document
2021-06-04 108 Redacted Document the validity of patents related to the Patents-in-Suit, such as U.S. Patent Nos. 8,497,393 (“the ’393…concerning [U.S. Patent No. 8,497,393] in association with the ’901 and ’066 patents,” asserting that…concerning the Related Patents and Applications, including U.S. Patent Nos. 8,497,393; 9,339,507; 9,358,…PTAB's 4 The '393 patent is U.S. Patent No. 8,497,393. Case 1:20-cv-00755-RGA-JLH Document…Hatch‐Waxman litigation involving the Patents‐in‐Suit and U.S. Patent Nos. 8,497,393; 9,339,507; and 9,358,240, External link to document
2021-06-04 109 Ex. 1 - Second Amended Complaint seq., involving United States Patent Nos. 9,593,066 (“the ’066 patent”) (attached as Exhibit A hereto…the expiration of the ’066 patent, the ’901 patent, and the ’793 patent, to manufacture, market, and… more claims of the ’066 patent, the ’901 patent, and the ’793 patent, which have been listed in …Liquidia has infringed the ’066 patent, the ’901 patent, and the ’793 patent; and …or more of the ’066 patent, the ’901 patent, and the ’793 patent, prior to the expiration External link to document
2020-07-16 11 Answer to Complaint AND Counterclaim UTC’s U.S. Patent No. 8,497,393, finding that the product claimed in the ʼ393 patent was not novel … UTC’s U.S. Patent No. 8,497,393, finding that the product claimed in the ʼ393 patent was not novel …assert a patent infringement action. Liquidia admits that U.S. Patent No. 9,593,066 (the “’066 patent”) and… and U.S. Patent No. 9,604,901 (the “’901 patent”) (collectively the “patents-in-suit”) each bear the…the ’066 patent is a product-by-process patent, and that the product claimed in the ’066 patent is novel External link to document
2021-06-15 117 Proposed Order claims of U.S. Patent Nos. 8,593,066 (the “’066 patent”) and 9,604,901 (the “’901 patent”), the terms…range of 15°C to 30°C) ’066 patent, claims 6 and 8; ’901 patent, claim 6 “stored” / “storing…and ordinary meaning ’066 patent, claims 6 and 8; ’901 patent, claim 6 1 The Court… plain and ordinary meaning ’066 patent, claims 1 and 8 “ambient temperature” …treprostinil,” appearing in claims 1 and 8 of the ʼ901 patent, but will issue its order regarding these terms External link to document
2021-06-21 125 Joint Claim Construction Brief in IPR2020-00770 regarding U.S. Patent No. 9,604,901 (“the ’901 patent”) (Paper 29, Joint Paper Concerning…statements made in the [Patent Owner’s Response] suggesting that the ’901 patent requires that treprostinil…expressly rejected by the Patent Office,” making the record clear to POSAs “that Patent Owner’s arguments …withdrawal of certain statements made before the Patent Trial and Appeal Board (“PTAB” or “Board”) in…Concerning Petitioner’s Request to Strike Portions of Patent Owner’s Paper Nos. 12 and 25 and Exhibits 2002 External link to document
2020-07-22 16 Complaint - Amended seq., involving United States Patent Nos. 9,593,066 (“the ’066 patent”) (attached as Exhibit A hereto…to the expiration of the ’066 patent, the ’901 patent, and the ’793 patent, to manufacture, market, and… or more claims of the ’066 patent, the ’901 patent, and the ’793 patent, which have been listed in …Liquidia has infringed the ’066 patent, the ’901 patent, and the ’793 patent; and…more of the ’066 patent, the ’901 patent, and the ’793 patent, prior to the expiration External link to document
2020-07-28 18 Proposed Order proceedings with respect to both U.S. Patent No. 9,593,066, and U.S. Patent No. 9,604,901. Plaintiff does …The parties agree to the timetable for initial patent disclosures as set forth in the chart attached …litigation within the next year. As Plaintiff’s U.S. Patent No. 10,716,793 issued on July 21, 2020, Defendant…understanding of Plaintiff’s claims regarding the ʼ793 patent, and therefore cannot advise whether it expects…Partes Review proceedings concerning the ʼ793 patent within the next year. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.